Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) executed an on-market repurchase of 48,700 H shares on 3 July 2026, paying a total of HKD 1.40 million. The shares were bought at prices ranging from HKD 27.96 to HKD 28.96, translating into a volume-weighted average cost of HKD 28.68 per share.

Following the transaction: • Issued shares (excluding treasury shares) decreased 0.036 % to 134.46 million. • Treasury shares increased to 1.76 million. • Total issued share capital remained unchanged at 136.22 million.

The repurchase was made under the mandate approved on 24 June 2026, which permits the company to buy back up to 13.47 million shares. To date, 238,300 shares—equivalent to 0.18 % of the share base at mandate approval—have been repurchased.

Under Hong Kong Stock Exchange rules, HANXBIO-B is restricted from issuing new shares or disposing of treasury shares until 2 August 2026. The board confirms that all repurchase procedures complied with the Exchange’s regulations and relevant laws.